RenovoRx (RNXT) Operating Income (2020 - 2026)
RenovoRx (RNXT) posted Operating Income of -$3.5 million for Q1 2026, up 1.5% sequentially from -$3.5 million in Q4 2025, and down 11.54% YoY from -$3.9 million in Q1 2025.
RenovoRx (RNXT) Operating Income (2020 - 2026) Analysis & Trends
RenovoRx has reported Operating Income for 7 years, with the latest figure at -$3.5 million in Q1 2026.
- Quarterly Operating Income fell 11.54% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.9 million (down 10.9% YoY) and the FY2025 annual result came in at -$12.5 million, down 14.04% from the prior year.
- Operating Income advanced to -$3.5 million in Q1 2026 per RNXT's latest filing, from -$3.5 million in the prior quarter.
- Over five years, Operating Income peaked at -$1.8 million in Q4 2023 and troughed at -$3.5 million in Q4 2025.
- A 5-year average of -$2.8 million and a median of -$3.0 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2024: Operating Income slumped 201.85% in 2022, then gained 24.07% in 2024.
- Over 5 years, Operating Income stood at -$2.2 million in 2022, then rose by 18.11% to -$1.8 million in 2023, then plunged by 48.11% to -$2.6 million in 2024, then tumbled by 33.81% to -$3.5 million in 2025, then advanced by 1.5% to -$3.5 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$3.5 million, -$3.5 million, and -$3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 | -3.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.35 Mn |
| Mar 31, 2026 | -3.47 Mn |
| Dec 31, 2025 | -3.52 Mn |
| Sep 30, 2025 | -3.20 Mn |
| Jun 30, 2025 | -2.68 Mn |
| Mar 31, 2025 | -3.11 Mn |
| Dec 31, 2024 | -2.63 Mn |
| Sep 30, 2024 | -2.83 Mn |
| Jun 30, 2024 | -3.03 Mn |
| Mar 31, 2024 | -2.48 Mn |
| Dec 31, 2023 | -1.78 Mn |
| Sep 30, 2023 | -2.98 Mn |
| Jun 30, 2023 | -3.38 Mn |
| Mar 31, 2023 | -3.26 Mn |
| Dec 31, 2022 | -2.17 Mn |
| Sep 30, 2022 | -2.16 Mn |
| Jun 30, 2022 | -2.61 Mn |
| Mar 31, 2022 | -3.01 Mn |
| Dec 31, 2021 | -2.36 Mn |
| Sep 30, 2021 | -1.40 Mn |